Frontiers in pediatrics · 2026
Comparative efficacy of quarterly vs. monthly triptorelin in Chinese girls with central precocious puberty: a 12-month observational study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cai Hongyi, Wu Wenyong, Yuan Xin, Zhang Ying, Yang Xiaohong, Huang Xiaozhen, Ai Zhuanzhuan, Li Dandan, Chen Ruimin
Аннотация
BACKGROUND: This study aimed to compare the clinical efficacy of quarterly (15 mg/90 days) versus monthly (3.75 mg/28 days) triptorelin formulations with respect to bone maturation, predicted adult height (PAH), and hormonal suppression in Chinese girls with central precocious puberty (CPP).
METHODS: This retrospective cohort study included 70 girls diagnosed with CPP at Fuzhou First General Hospital from March 2023 to 2025. Participants were assigned to either a quarterly regimen (triptorelin 15 mg every 90 days, n = 32) or a monthly regimen (triptorelin 3.75 mg every 28 days, n = 38). The evaluated outcomes included bone age (BA; TW3 method), PAH, serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH) concentrations, uterine and ovarian volumes, body mass index (BMI), and adverse events, assessed at baseline, 6 months, and 12 months.
RESULTS: After 12 months of treatment, both regimens achieved effective and comparable suppression of LH (quarterly: 0.30 ± 0.19 IU/L; monthly: 0.30 ± 0.26 IU/L; both P < 0.001 vs. baseline) and FSH (quarterly:1.22 ± 0.91 IU/L; monthly: 1.31 ± 0.65 IU/L; P < 0.05 vs. baseline). Improvements in PAH were also comparable between groups (quarterly: 3.95 ± 2.97 cm; monthly: 2.91 ± 2.70 cm; P = 0.790). No significant between-group differences were observed in BA maturation, growth velocity, or uterine and ovarian volumes (P > 0.05). BMI increased significantly in both groups (quarterly: from 16.96 ± 2.10 to 17.89 ± 2.53 kg/m2, P = 0.01; monthly: from 16.89 ± 2.06 to 17.50 ± 2.03 kg/m2, P = 0.008), with no significant differences between regimens. Three patients experiencing a "flare-up" had a larger mean baseline uterine volume (6.95 mL) compared with the remaining 67 patients (2.38 mL).
CONCLUSION: Quarterly triptorelin demonstrated efficacy comparable to that of monthly administration in suppressing puberty and improving PAH in Chinese girls with CPP.
METHODS: This retrospective cohort study included 70 girls diagnosed with CPP at Fuzhou First General Hospital from March 2023 to 2025. Participants were assigned to either a quarterly regimen (triptorelin 15 mg every 90 days, n = 32) or a monthly regimen (triptorelin 3.75 mg every 28 days, n = 38). The evaluated outcomes included bone age (BA; TW3 method), PAH, serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH) concentrations, uterine and ovarian volumes, body mass index (BMI), and adverse events, assessed at baseline, 6 months, and 12 months.
RESULTS: After 12 months of treatment, both regimens achieved effective and comparable suppression of LH (quarterly: 0.30 ± 0.19 IU/L; monthly: 0.30 ± 0.26 IU/L; both P < 0.001 vs. baseline) and FSH (quarterly:1.22 ± 0.91 IU/L; monthly: 1.31 ± 0.65 IU/L; P < 0.05 vs. baseline). Improvements in PAH were also comparable between groups (quarterly: 3.95 ± 2.97 cm; monthly: 2.91 ± 2.70 cm; P = 0.790). No significant between-group differences were observed in BA maturation, growth velocity, or uterine and ovarian volumes (P > 0.05). BMI increased significantly in both groups (quarterly: from 16.96 ± 2.10 to 17.89 ± 2.53 kg/m2, P = 0.01; monthly: from 16.89 ± 2.06 to 17.50 ± 2.03 kg/m2, P = 0.008), with no significant differences between regimens. Three patients experiencing a "flare-up" had a larger mean baseline uterine volume (6.95 mL) compared with the remaining 67 patients (2.38 mL).
CONCLUSION: Quarterly triptorelin demonstrated efficacy comparable to that of monthly administration in suppressing puberty and improving PAH in Chinese girls with CPP.